Litcius/Paper detail

Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells

Phatchara Norbnop, Praewphan Ingrungruanglert, Nipan Israsena, Kanya Suphapeetiporn, Vorasuk Shotelersuk

2020Scientific Reports45 citationsDOIOpen Access PDF

Abstract

Platelet demand has increased around the world. However, the inadequacy of donors, the risk of transfusion-transmitted infections and associated reactions, and the refractory nature of platelet transfusions are among the limitations of allogeneic platelet transfusions. To alleviate these problems, we propose generating platelets in a laboratory that do not induce alloimmunity to human leukocyte antigen (HLA) class I, which is a major cause of immune reaction in platelet transfusion refractoriness. Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) of a healthy Thai woman. We then knocked out the β2-microglobulin (β2m) gene in the cells using paired CRISPR/Cas9 nickases and sequentially differentiated the cells into haematopoietic stem cells (HSCs), megakaryocytes (MKs) and platelets. Silencing of HLA class I expression was observed on the cell surface of β2m-knockout iPSCs, iPSC-derived HSCs, MKs and platelets. The HLA-universal iPSC-derived platelets were shown to be activated, and they aggregated after stimulation. In addition, our in vivo platelet survival experiments demonstrated that human platelets were detectable at 2 and 24 hours after injecting the β2m-KO MKs. In summary, we successfully generated functional iPSC-derived platelets in vitro without HLA class I expression by knocking out the β2m gene using paired CRISPR/Cas9 nickases.

Topics & Concepts

Induced pluripotent stem cellPlateletHaematopoiesisImmunologyHuman leukocyte antigenStem cellBiologyAlloimmunityCell biologyImmune systemAntigenGeneEmbryonic stem cellGeneticsCRISPR and Genetic EngineeringPluripotent Stem Cells ResearchPlatelet Disorders and Treatments